These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27855197)

  • 21. Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
    Sitohy B; Chang S; Sciuto TE; Masse E; Shen M; Kang PM; Jaminet SC; Benjamin LE; Bhatt RS; Dvorak AM; Nagy JA; Dvorak HF
    Am J Pathol; 2017 Oct; 187(10):2337-2347. PubMed ID: 28736316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.
    Avery RL; Gordon GM
    JAMA Ophthalmol; 2016 Jan; 134(1):21-9. PubMed ID: 26513684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is resveratrol a potential substitute for leuprolide acetate in experimental endometriosis?
    Bayoglu Tekin Y; Guven S; Kirbas A; Kalkan Y; Tumkaya L; Guvendag Guven ES
    Eur J Obstet Gynecol Reprod Biol; 2015 Jan; 184():1-6. PubMed ID: 25462211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wenyang Huoxue Jiedu formula inhibits thin-cap fibroatheroma plaque formation via the VEGF/VEGFR signaling pathway.
    Chen S; Ye ZQ; Li ZW; Zhao CX; Chen GJ; Zhou JZ; Wang C; Huang RL; Hong YD
    J Ethnopharmacol; 2018 Jun; 219():213-221. PubMed ID: 29551453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis.
    Ricci AG; Olivares CN; Bilotas MA; Meresman GF; Barañao RI
    Reprod Sci; 2011 Jul; 18(7):614-22. PubMed ID: 21266664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [VEGF-receptor inhibitors for anti-angiogenesis].
    Shibuya M
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):498-503. PubMed ID: 14639004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.
    Su M; Huang J; Li J; Qin X; Tang X; Jin F; Chen S; Jiang C; Zou Z; Peng K; Nuruzzaman M; Zhang J; Luo J; Liu S; Luo Z
    Oncotarget; 2016 Apr; 7(14):19018-30. PubMed ID: 26967559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
    Tarallo V; De Falco S
    Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
    Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
    Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
    Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
    Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
    Ding F; Liu B; Wang Y
    J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipoxin A4 inhibits the development of endometriosis in mice: the role of anti-inflammation and anti-angiogenesis.
    Xu Z; Zhao F; Lin F; Chen J; Huang Y
    Am J Reprod Immunol; 2012 Jun; 67(6):491-7. PubMed ID: 22229383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
    Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management.
    Jiang L; Ping L; Yan H; Yang X; He Q; Xu Z; Luo P
    Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):823-835. PubMed ID: 32597258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor gene polymorphisms contribute to the risk of endometriosis: an updated systematic review and meta-analysis of 14 case-control studies.
    Li YZ; Wang LJ; Li X; Li SL; Wang JL; Wu ZH; Gong L; Zhang XD
    Genet Mol Res; 2013 Apr; 12(2):1035-44. PubMed ID: 23613250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.
    Qi WX; Min DL; Shen Z; Sun YJ; Lin F; Tang LN; He AN; Yao Y
    Int J Cancer; 2013 Jun; 132(12):2967-74. PubMed ID: 23225494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.
    Ishak RS; Aad SA; Kyei A; Farhat FS
    Crit Rev Oncol Hematol; 2014 May; 90(2):152-64. PubMed ID: 24355408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic phytochemicals and medicinal herbs.
    Jeong SJ; Koh W; Lee EO; Lee HJ; Lee HJ; Bae H; Lü J; Kim SH
    Phytother Res; 2011 Jan; 25(1):1-10. PubMed ID: 20564543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.